[
    [
        {
            "time": "2018-01-02",
            "original_text": "Biotech, M&A, Off to a Strong Start in 2018: More Deals to Follow?",
            "features": {
                "keywords": [
                    "Biotech",
                    "M&A",
                    "Strong Start"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Biotech, M&A, Off to a Strong Start in 2018: More Deals to Follow?",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Reading the Estimates for Novartis’s Alcon in 4Q17",
            "features": {
                "keywords": [
                    "Novartis",
                    "Alcon",
                    "Estimates"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Reading the Estimates for Novartis’s Alcon in 4Q17",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "What’s Expected of Novartis’s Sandoz Segment in 4Q17?",
            "features": {
                "keywords": [
                    "Novartis",
                    "Sandoz",
                    "Expected"
                ],
                "sentiment_score": 0.55,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What’s Expected of Novartis’s Sandoz Segment in 4Q17?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]